AMI Cardiogenic Shock

Early Stabilization Can Improve Outcomes in Cardiogenic Shock

Impella® heart pumps have the ability to stabilize patient hemodynamics, unload the left ventricle, perfuse end organs, and allow for recovery of the native heart in patients with ongoing cardiogenic shock. Identifying patients early, treating them with a proven protocol, and following them with hemodynamic monitoring and aggressive down titration of inotropes and vasopressors can reverse the downward spiral of cardiogenic shock and help patients achieve myocardial recovery.

Explore the Education Library


Final Results from the NCSI Study Demonstrate the Benefit of Early Cardiac Unloading with Impella

The NCSI Study demonstrates a 71% survival to discharge with greater than 90% native heart recovery when best practices are used, including placement of an Impella heart pump prior to revascularization.


Achieving >70% AMI Cardiogenic Shock Survival: Insight from National Cardiogenic Shock Initiative (NCSI) Study

William O'Neill, MD, explains how cardiac power output (CPO) and pulmonary artery pulsatility index (PAPI) are used to drive care for patients after angioplasty.


Cardiogenic Shock Patients Can Achieve Heart Recovery

Dr. Shelley Hall, chief of transplant cardiology and mechanical support/heart failure at Baylor University Medical Center, discusses the challenges of creating trials to advance the science of cardiogenic shock.